Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI

Sichuan University

Status: Not yet enrolling

Conditions: High-grade Glioma

Treatments: Device: adaptive radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06201351

Trial No. 1460, 2023

Details and patient eligibility

About

The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.

Full description

To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The relationship between changes and patient survival was analyzed.A predictive model was established to provide individualized adaptive radiotherapy for patients.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years old;
2. High-grade glioma was confirmed by pathology after surgery;
3. ECOG score 0-2 points;
4. Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
5. Baseline data available.

Exclusion criteria

1. The pathological diagnosis is not clear;
2. No synchronous chemotherapy/adjuvant chemotherapy < 6 cycles;
3. There are other malignant tumors;
4. Previously radiotherapy to the head;
5. Interruption of radiotherapy for more than 5 days;
6. Failure to collect baseline data.

Trial design

60 participants in 1 patient group

Adaptive radiotherapy group

Description:

MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.

Treatment:

Device: adaptive radiotherapy